Iovance Biotherapeutics (IOVA)
(Delayed Data from NSDQ)
$9.35 USD
-0.04 (-0.43%)
Updated Oct 1, 2024 04:00 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Income Statements
Fiscal Year end for Iovance Biotherapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 1 | 0 | 0 | 0 | 0 |
Cost Of Goods | 11 | 0 | 0 | 0 | 0 |
Gross Profit | -10 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 451 | 399 | 343 | 262 | 207 |
Income After Depreciation & Amortization | -461 | -399 | -343 | -262 | -207 |
Non-Operating Income | 13 | 3 | 0 | 2 | 9 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -448 | -396 | -342 | -260 | -198 |
Income Taxes | -3 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -444 | -396 | -342 | -260 | -198 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -444 | -396 | -342 | -260 | -198 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -431 | -389 | -334 | -259 | -209 |
Depreciation & Amortization (Cash Flow) | 30 | 10 | 9 | 3 | -2 |
Income After Depreciation & Amortization | -461 | -399 | -343 | -262 | -207 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 235.13 | 159.26 | 153.41 | 138.30 | 124.34 |
Diluted EPS Before Non-Recurring Items | -1.89 | -2.49 | -2.23 | -1.88 | -1.59 |
Diluted Net EPS (GAAP) | -1.89 | -2.49 | -2.23 | -1.88 | -1.59 |
Fiscal Year end for Iovance Biotherapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | 31.11 | 0.72 | 0.48 | 0.47 | 0.24 |
Cost Of Goods | 31.37 | 7.26 | 4.37 | 4.34 | 2.05 |
Gross Profit | -0.26 | -6.55 | -3.88 | -3.87 | -1.81 |
SG&A, R&D, and Dept/Amort Expenses | 101.65 | 111.17 | 117.37 | 114.49 | 108.28 |
Income After SG&A, R&D, and Dept/Amort Expenses | -101.91 | -117.72 | -121.25 | -118.36 | -110.09 |
Non-Operating Income | 3.36 | 3.34 | 3.12 | 3.36 | 3.08 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -98.56 | -114.38 | -118.14 | -115.00 | -107.01 |
Income Taxes | -1.46 | -1.41 | -1.76 | -1.24 | -0.48 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -97.10 | -112.98 | -116.38 | -113.76 | -106.53 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -97.10 | -112.98 | -116.38 | -113.76 | -106.53 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | 284.82 | 266.22 | 255.95 | 245.82 | 224.48 |
Diluted EPS Before Non-Recurring Items | -0.34 | -0.42 | -0.45 | -0.46 | -0.47 |
Diluted Net EPS (GAAP) | -0.34 | -0.42 | -0.46 | -0.46 | -0.47 |